Solos Endoscopy, Inc. (OTC PINK: SNDY) is pleased to announce that the Companys MammoView(R) Breast Endoscopy System can aid in giving women the best prognosis for recovery by detecting breast cancer at an earlier stage than conventional methods (http://www.solosendoscopy.com/ductoscope-sell-sheet-final.pdf).
Physicians using the MammoView(R) Breast Endoscopy System can detect cancerous cells at .25mm compared to 1cm using the average conventional screening methods. Micro endoscopic detection allows physicians to clearly see the boundary between healthy and abnormal tissue. As a result, the MammoView(R) can improve the chances that breast cancer be detected at an early stage and treated successfully.
Solos Endoscopy believes that all women, not just the rich and famous, need to benefit from early detection of breast cancer. Women from all walks of life need to know their options for detecting and preventing breast cancer, short of a mastectomy. Breast cancer is the most common cancer among women in the world. Of the five million women expected to die from breast cancer in the next decade, 70 percent will live in under developed countries.
Too many women discover they have been diagnosed with “breast cancer” at a point when their options for treatment are limited. The importance of early detection to treatment is well-recognized for reducing women’s chances of dying from breast cancer. Breast health awareness, is a given in this country, however, many insurance companies do not normally cover mammary ductoscopy procedures for early detection.
It is well documented that early detection is crucial in the fight against breast cancer. The MammoView(R) System is designed to significantly reduce the detection time and I believe it is an essential tool for early breast cancer screening and treatment, stated Bob Segersten, President of Solos Endoscopy, Inc.
The Solos MammoView(R) Breast Endoscopy System can help more women detect early signs of disease and thereby seek advice as to multiple treatment options that early detection can offer. Experts at theBreast Health Global Initiative(http://portal.bhgi.org/Pages/Default.aspx) and elsewhere propose tiered guidelines for diagnosis and treatment based on what’s suitable and affordable for a country or community. Solos Endoscopy supports implementing such guidelines now and giving Women more options for the early screening and detection of breast cancer.
The Solos MammoView(R) Breast Endoscopy System employs advanced microendoscopes and optical technology which gives physicians sharp images of the milk ducts where the majority of breast cancer arises. Solos Endoscopy instruments are FDA approved. Upon Solos Endoscopys receipt of its ISO 13485 Certification, the Company will be able to place the CE Mark on its entire MammoView(R) instrument line which will allow the instrument line to be sold globally. Both Solos and Expert Resource believe the ISO 13485 Certification and CE Mark initiative will be completed within the next few months.
Solos Endoscopy’s MammoView(R) System Offers Women Early Breast Cancer Detection
